Towards Better Diagnosis and Care: How is Synapsing Advancing Diagnosis and Management of Psychiatric Symptoms in MDs and NDs

Proper diagnosis not only increases the likelihood of successful outcomes and faster recovery but also prevents unnecessary or harmful treatments, reduces healthcare costs, and fosters trust between patients and providers. On the contrary, misdiagnosis can lead to delayed or inappropriate care, prolonged suffering, and avoidable complications, underscoring the critical importance of getting the diagnosis right from the outset.

The Problem: Overlapping Symptoms and Treatment Gaps

Mental disorders (MDs), including depression and schizophrenia, along with neurodegenerative disorders (NDs) such as Alzheimer's disease, are linked by a common issue: impaired communication within the brain. This disruption results in similar emotional, behavioral, and cognitive symptoms. Sadly, existing treatments, such as antidepressants and antipsychotics, frequently fail for ND patients, and many individuals with MDs become resistant to treatment. Consequently, the scarcity of effective treatment alternatives places a considerable burden on patients, their families, and society at large.

The role of Synapsing in Advancing Diagnosis and Care

Synapsing is a groundbreaking European project bringing together experts from 13 partners across the continent, all united by a common goal: to reduce the heavy burden of untreated psychiatric symptoms in both mental disorders (MDs) and neurodegenerative disorders (NDs).

But how exactly is Synapsing changing the game when it comes to diagnosis and patient care? Let’s break it down.

Faster, More Accurate Diagnosis with Blood Biomarkers

One of the biggest challenges in treating MDs and NDs is the difficulty in diagnosing these conditions quickly and accurately. Symptoms often overlap, leading to misdiagnosis and delays in getting the right treatment. Synapsing is tackling this head-on by searching for blood biomarkers - biological clues in the blood - that can provide a faster, more objective way to diagnose mental disorders and clearly distinguish them from neurodegenerative diseases. This means patients can get the right diagnosis sooner, avoiding unnecessary treatments and frustration.

Personalized Treatment Through Monitoring and Patient Stratification

Not all patients respond the same way to treatments, and some therapies can be inefficient or even harmful if not properly matched. Synapsing is developing blood tests that don’t just help diagnose but also monitor how well a patient is responding to treatment. This allows for therapy adjustments in real time and identifies which patients will benefit most from specific interventions, leading to more personalized and effective care.

Understanding the Brain to Discover New Treatments

To develop better treatments, Synapsing is diving deep into the biology of these disorders. Using post-mortem brain tissue and special stem cell models derived from patients, researchers are studying how synapses - the connections between brain cells - malfunction in both mental and neurodegenerative disorders. This research is crucial for uncovering the underlying causes and identifying new targets for future therapies.

Addressing Social Factors to Prevent Mental Health Issues

Mental health isn’t just about biology - it’s also shaped by social and economic factors. Synapsing is conducting large-scale studies involving over 2,000 individuals across Europe to identify modifiable social risk factors that contribute to psychiatric symptoms. By understanding these influences, the project aims to inform evidence-based policies that can reduce health disparities and prevent mental health problems before they start.

Building a Stronger Network for Knowledge and Care

Beyond research, Synapsing is creating a unique clinical cohort called BIOMIND, combining clinical data and biological samples from patients with a wide range of mental and neurodegenerative disorders. This rich resource, along with shared expertise and cutting-edge tools, will help update clinical guidelines and strengthen collaboration among scientists, doctors, and policymakers across Europe.

Based on these innovative approaches, Synapsing is paving the way for faster diagnosis, more efficient treatments, and more adequate mental healthcare, bringing hope to millions affected by these complex disorders.

Privanova’s Role

Privanova will ensure that the Synapsing project upholds the highest ethical and regulatory standards. Our role includes:

• Interpreting and implementing ethical requirements from the European Commission.
• Delivering a policy report with recommendations to reduce social disparities in mental health.
• Establishing an Ethics Advisory Board, featuring both internal and external experts, to guide the consortium on ethical and social issues.
• Leading compliance efforts to align with data protection regulations and responsible research and innovation.
• Organising the SynergyHealth cluster workshop, fostering collaboration between MD and ND researchers and clinicians.